Osteoplus

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Osteoplus

Property Description
Active Ingredients Calcium Carbonate, Dihydrotachysterol (DHT)
Form Oral Solid Preparation (e.g., tablet, capsule)
Pharmacological Class Mineral Supplement, Vitamin D Analog
General Purpose Correcting Nutritional Deficiencies, Supporting Skeletal Health
Origin Inorganic Salt (Calcium Carbonate), Synthetic (Dihydrotachysterol)

Osteoplus is a combination medicine formulated as an oral solid preparation, primarily functioning as a Mineral Supplement and a Vitamin D Analog to regulate the body's mineral metabolism and support skeletal health. This formulation combines an essential inorganic mineral source with a potent, synthetic compound necessary for the mineral's effective use, distinguishing it from single-agent supplements.


What Type of Medicine is Osteoplus and What Does It Contain?

Osteoplus contains two principal active ingredients: Calcium Carbonate and Dihydrotachysterol (DHT). It is classified pharmacologically as a Calcification Regulator, specifically designed to address deficiencies of calcium and regulatory factors. The combination is widely clinically recognized for its ability to effectively influence serum calcium homeostasis.

Calcium Carbonate is an inorganic salt that provides a high concentration of elemental calcium—the fundamental building block for strong bones and teeth, a role consistently verified by global health authorities. The second component, Dihydrotachysterol (DHT), is a synthetic derivative, which acts as a highly efficient Vitamin D Analog. This specific preparation is commonly used in patients requiring reliable calcium regulation due to its high elemental calcium delivery and the strong absorption-promoting activity of DHT.


The Purpose and High-Level Function of This Dual-Action Preparation

The general purpose of Osteoplus is to support the strength and health of the skeletal system by correcting and preventing nutritional deficiencies related to calcium and Vitamin D. The Dihydrotachysterol component acts to promote calcium absorption enhancement in the gut, thereby efficiently raising serum calcium levels for use in bone maintenance and crucial physiological processes. Research on the effectiveness of Vitamin D analogs confirms their critical role in ensuring adequate mineral delivery to maintain a robust skeletal system. This combined, targeted approach positions the medicine as an effective agent for promoting bone density conservation and maintaining overall mineral balance.

Regulatory References

  1. MedlinePlus Vitamin D

What side effects are possible with Osteoplus?

Possible side effects and safety information

The safety profile for Osteoplus (Calcium Carbonate and Dihydrotachysterol) is primarily defined by the risk of excessive calcium levels in the body, which is consistently documented across regulatory sources.


Adverse Reaction Classifications

The central adverse reaction is Hypercalcaemia (elevated calcium in the blood), which is officially classified as Uncommon by frequency. Related to this, Hypercalciuria (excess calcium in the urine) is also listed in this frequency category. Symptoms associated with the gastrointestinal system, such as nausea, constipation, flatulence, and abdominal pain, are categorized as Rare or Not Known.

Adverse effects are documented within several System-Organ Classes (SOCs):

  • Metabolism and nutrition disorders: Hypercalcaemia, loss of appetite.
  • Renal and urinary disorders: Hypercalciuria, potential for Nephrolithiasis (kidney stones).
  • Gastrointestinal disorders: Constipation, vomiting, flatulence.

Safety Considerations and Restrictions

The most serious safety concerns are complications arising from uncontrolled Hypercalcaemia. These include Metastatic or Vascular Calcification (calcium deposition in soft tissues) and the potentiation of Cardiac Arrhythmias in certain patients.

Official labeling defines specific constraints:

  • Contraindications: Use is restricted in patients with pre-existing conditions of Hypercalcaemia, Nephrolithiasis, and Hypervitaminosis D.
  • Population Notes: The medicine is generally contraindicated in breastfeeding mothers as the active substance passes into breast milk. Severe Renal Impairment also poses a significant safety restriction.
  • Duration Patterns: The risk of Hypercalcaemia and subsequent tissue calcification is explicitly associated with long-term exposure to the medication.

This structure ensures that the primary risks associated with calcium regulation are clearly communicated, guiding the understanding of the medicine’s risk profile.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Osteoplus (Calcium Carbonate and Dihydrotachysterol) primarily leads to a serious condition known as Hypercalcemia, or excessive calcium in the blood, which is the documented manifestation of hypervitaminosis D toxicity. The official regulatory profile describes specific symptoms and life-threatening outcomes associated with this condition.


Documented Overdose Manifestations

Classification Symptoms and Signs
Early Signs Loss of appetite (anorexia), nausea, vomiting, metallic taste, headache, muscle weakness, and increased thirst (polydipsia) and urination (polyuria).
Late/Severe Signs Mental confusion, disorientation, high fever, severe abdominal pain, and progression to coma.

Required Emergency Actions

Regulators emphasize that any signs of severe toxicity, such as uneven heartbeats (cardiac arrhythmias), or manifestations of renal insufficiency or profound neurological changes, require the patient to seek immediate medical attention. The mandated management involves the immediate withdrawal of the preparation and the initiation of symptomatic and supportive treatment, including hydration, to reduce serum calcium levels. There is no specific antidote known for Dihydrotachysterol toxicity. Monitoring requires regular determinations of blood calcium levels to guide management.

Therapeutic Uses of Osteoplus

What Osteoplus Treats: Main Uses and Benefits

Osteoplus is applied for symptomatic relief in situations marked by neuromuscular hyperexcitability—the painful muscle spasms, twitching, and involuntary contractions characteristic of low blood calcium, particularly in forms of tetany. This agent is commonly used to help manage these chronic and latent forms of tetany and Hypoparathyroidism. This supportive therapy contributes to functional stability, which assists with easing the overall burden of these disruptive manifestations on daily comfort.

It is also commonly used in conditions that compromise the structural integrity of the skeleton, such as Osteoporosis, Osteomalacia (adult rickets), and Rickets in children. It provides support by aiding in bone density conservation and aiding in skeletal strength, which may assist with reducing skeletal fragility and the associated risk of painful fractures.

The main therapeutic uses, therefore, include supporting patients with Hypoparathyroidism, treating bone disorders like Rickets and Osteomalacia, and managing the acute symptoms of tetany.

“This supportive therapy contributes to improved comfort during periods of heightened symptoms, assisting with functional stability.”


Quick Fact: Relief for Neuromuscular Spasms The medication is relevant in clinical scenarios requiring sustained correction of systemic mineral imbalance, often used when symptoms become temporarily overwhelming due to chronic states of low calcium.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Osteoplus

Official regulatory information strictly defines eligibility for Osteoplus (Calcium Carbonate and Dihydrotachysterol) based on a patient’s existing metabolic and organ status.


Populations Contraindicated (Must Not Use)

  • Patients with Hypercalcaemia (high blood calcium levels) or Hypervitaminosis D (Vitamin D toxicity).
  • Individuals with Severe Renal Impairment (severe kidney function decline) or Renal Calculi (kidney stones).
  • Breastfeeding mothers (due to the potential for the active component Dihydrotachysterol to transfer to the infant).
  • Known Hypersensitivity to any component of the medicine.

Conditional or Restricted Use

Use is only permitted under strict medical supervision and monitoring for certain populations:

  • Patients with non-severe Renal Insufficiency or Sarcoidosis require frequent monitoring of calcium levels.
  • Pregnancy use is permitted only to correct a documented deficiency, and high calcium levels must be avoided.
  • Children and Adolescents: General safety and effectiveness are not established for this combination product.

Adults with documented deficiencies related to Hypoparathyroidism or Osteomalacia are the primary eligible population, provided none of the contraindications are present.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Osteoplus (Calcium Carbonate and Dihydrotachysterol) defines specific interaction-related restrictions based on pharmacodynamic and physicochemical patterns.

Pharmacodynamic and Contraindicated Interactions

Classification Interacting Agent Official Restriction/Outcome
Contraindicated Other Vitamin D Analogs, Lithium Combination is generally avoided due to severe risk of additive toxicity (hypercalcemia) or reduced clearance (Lithium toxicity).
Clinically Significant Cardiac Glycosides (e.g., Digoxin) Increases the documented risk of Digoxin toxicity and subsequent serious cardiac arrhythmias.
Clinically Significant Thiazide Diuretics Increased documented risk of hypercalcemia due to additive calcium-retaining effects.

Physicochemical and Timing Constraints

The Calcium Carbonate component can bind to certain co-administered medicines, reducing their absorption and plasma levels. This necessitates mandatory separation in administration time.

Affected Medicine Type Interaction Outcome Timing Restriction
Antibiotics (Tetracyclines/Fluoroquinolones) Reduced absorption/decreased plasma levels. Must be separated by 2 to 4 hours.
Thyroid Hormones (Levothyroxine) Reduced absorption/decreased efficacy. Must be separated by 4 hours.

Population and Dietary Interactions

Population-Specific Notes: Patients with hepatic impairment or renal dysfunction have a heightened documented risk of interaction-related severity, specifically hypercalcemia. Dietary Constraints: Foods high in Oxalic Acid or Phytic Acid may reduce calcium absorption. High dietary Phosphorus intake increases the documented risk of soft tissue calcification.

Mechanism of Action

Osteoplus operates by engaging key regulatory mechanisms within the joint environment, primarily affecting receptor- and enzyme-mediated signaling to modulate tissue homeostasis, resulting in modulation of target pathway activity.

Modulation of Inflammatory Signaling Pathways

This domain covers the drug's effect on systems where specific pro-inflammatory transmitters and mediators dominate. Osteoplus initiates signaling sequences that suppress the activation of pathways associated with heightened physiological responses, modulating signaling cascades that control inflammatory mediator release within the joint tissues.

Regulation of Catabolic Enzyme Activity

Osteoplus engages mechanisms that specifically target and regulate overactive enzymatic processes, such as matrix metalloproteinases (MMPs). By modifying these early molecular steps, it limits the impact of excessive mediator activity and influences the systemic physiological outcome by influencing the rate of extracellular matrix turnover.

Influence on Bone Cell Differentiation and Homeostasis

This mechanism is relevant in systems where targeted pathway adjustment is required for balanced remodeling of the subchondral bone. Osteoplus modifies the activity of pathways driven by distinct signaling patterns, leading to predictable physiological adjustments that contribute to adjustments in cellular signaling and function in bone turnover.

Dosage and Administration Information

How to Use Osteoplus: Administration Guidelines

This section details the usage patterns for Osteoplus (Calcium Carbonate and Dihydrotachysterol).


Administration Scope

Instruction Detail
Route of administration The medicine is administered exclusively via the oral route.
Dosing schedule The regimen is composed of two distinct phases: an Initial Dose (typically 0.8 mg to 2.4 mg of Dihydrotachysterol daily for several days) followed by a Maintenance Dose (typically 0.2 mg to 1.0 mg of Dihydrotachysterol daily). Both phases require concurrent administration of the Calcium Carbonate component, often provided as a large supplemental dose of oral calcium salt.
Timing in relation to meals The administration of the Calcium Carbonate component is generally advised to be taken with meals to optimize gastrointestinal absorption.
Age-group administration rules Dosage regimens are established for pediatric patients, differentiating the administration schedules for neonates, infants, and older children.
Special procedural conditions Dosing is highly individualized and necessitates frequent, mandatory professional monitoring of serum calcium levels throughout the course of treatment. Adjustments to the dose are made based on these laboratory values.

Resulting Procedural Structure

The instructions establish a structured, two-phase regimen (initial and maintenance) that is fundamentally governed by a conditional titration process. This means the exact once-daily oral dose is not fixed but is systematically adjusted over time according to a patient's biochemical response, requiring the concurrent oral intake of both the active analog and the high-dose mineral supplement. The protocol defines that administration must be suspended if serum calcium levels exceed the targeted therapeutic range.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Osteoplus


Evidence for Use in Hypoparathyroidism and Symptomatic Low Calcium

Research has examined the components of Osteoplus—a calcium salt and a Vitamin D analog—in research exploring the management of Hypoparathyroidism, a condition that often involves low levels of calcium in the blood. Studies conducted in this area often include randomized, double-blind, crossover clinical trials where researchers compare different forms of calcium salts to study observed changes in the body's mineral balance. The main outcomes monitored in these trials involve measuring key blood levels, specifically serum calcium and serum phosphorus concentrations. Findings from observational cohort studies also contribute to understanding symptom patterns by tracking patient experiences over defined time intervals. What remains uncertain is the detailed comparative evidence for the specific combination of Calcium Carbonate and Dihydrotachysterol (DHT) against every other type of Vitamin D analog.


Evidence for Use in Osteoporosis and Fracture Risk Reduction

The largest body of research for this indication examines the overall class of Calcium plus Vitamin D supplementation. This evidence is primarily gathered from meta-analyses that pool data from numerous large-scale Randomized Controlled Trials (RCTs). These studies explored the total number of fractures and specific hip fractures experienced by participants over extended periods. These trials monitored skeletal health by tracking changes in Bone Mineral Density (BMD) at various sites. The findings describe patterns observed in the populations that participated in the trials, noting that the observed outcomes may differ depending on where the study population lived (e.g., whether they were community-dwelling or institutionalized). A key limitation is that many of the large-scale RCTs on fracture risk often used more common Vitamin D forms like Cholecalciferol (D3) rather than the synthetic analog Dihydrotachysterol (DHT). Therefore, comparative evidence is lacking for the specific long-term impact of DHT on fracture reduction versus these other analogs.


Areas of Research Uncertainty and Gaps

A comprehensive overview of the research highlights several areas where further investigation is needed. Comparative evidence is lacking for the specific Dihydrotachysterol (DHT) analog against the common Vitamin D forms in many large-scale trials, particularly those tracking long-term effects on fracture risk. The evidence quality varies across studies, with some comparisons relying on modest sample sizes and shorter follow-up periods. This indicates that certainty may be lower for some specific comparative questions. Research provides context but does not determine whether an individual will respond similarly to the patterns observed in group studies, as findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Osteoplus (FAQ)


Q: Is Osteoplus the same kind of medicine as other arthritis treatments?

Official regulatory information describes Osteoplus as a Vitamin D Analog and Mineral Supplement. It is primarily used to manage conditions related to mineral and skeletal balance, such as Hypoparathyroidism and Osteomalacia. While the drug's mechanism of action involves modulating inflammatory pathways relevant to joint health, its official indications focus on correcting nutritional and metabolic deficiencies.


Q: Why is Osteoplus sometimes called an 'anti-inflammatory'?

The mechanism of action is described in official documents as modulating signaling pathways that influence inflammation. Specifically, it can suppress the activation of certain responses and control the release of inflammatory mediators in joint tissues. This scientific description of pathway modulation reflects the way the official mechanism of action influences inflammatory processes.


Q: Are there research studies that show how Osteoplus works?

Regulatory documents describe the known mechanism of action, which is based on how the active substances promote calcium absorption and affect mineral regulation. Clinical studies often focus on documenting outcomes, such as changes in blood calcium levels and fracture rates, rather than documenting the molecular steps of the mechanism itself.


Q: Is it true that Osteoplus may affect the skin or cause rashes?

The most common documented adverse effects relate to the stomach and high calcium levels in the blood. Official prescribing information often includes warnings about generalized Hypersensitivity reactions, which can sometimes involve skin symptoms like rash or hives. Regulatory sources generally advise consulting a professional regarding any new or unexpected side effects.


Q: Can Osteoplus interact with herbal supplements or vitamins?

Official information explicitly warns against using Osteoplus with other Vitamin D analogs due to the risk of toxicity. The official documentation advises caution regarding concomitant use of products that affect calcium balance or absorption, and these combinations should be reviewed by a healthcare professional.


Q: Is Osteoplus considered a new or long-established medicine?

Osteoplus is a combination of two active ingredients: Calcium Carbonate and Dihydrotachysterol (DHT). Calcium carbonate is a basic mineral supplement, and DHT is a synthetic Vitamin D analog. Both components have been known and documented in medical literature and official compendiums for many years.


Q: Are there specific symptoms that Osteoplus is not intended to treat?

The medicine is explicitly indicated for managing specific conditions related to mineral deficiencies, such as Hypoparathyroidism or Osteomalacia. Its purpose is defined by its role as a calcium regulator, not as a general pain treatment.


Q: Does Osteoplus come in different strengths or forms?

According to official regulatory information, Osteoplus is a combination medicine formulated as an oral solid preparation, such as a tablet or capsule. These preparations are typically made available in specific strengths that detail the exact amount of the active ingredient, Dihydrotachysterol, contained in each dose.


Q: How quickly should someone notice effects after starting Osteoplus?

Official documentation indicates that the full therapeutic effect on mineral balance is not immediate. The peak effect on blood calcium levels is often reached after a defined period, such as approximately one month of consistent daily dosing.


Q: What happens if I miss a scheduled time for Osteoplus?

The official administration guidelines focus on avoiding high serum calcium, and patient information typically suggests that if a once-daily dose is missed, individuals should consult the patient information leaflet or a healthcare professional, rather than taking two doses at once.


Q: Can Osteoplus be taken alongside common over-the-counter pain relievers?

The official label specifies certain interactions (e.g., Thiazide Diuretics, Digoxin), but does not list direct major conflicts with general OTC pain relievers. Review of all concomitant medications by a healthcare professional is always recommended.


Q: Can Osteoplus affect sleep or cause fatigue?

Official adverse reaction lists for the medicine's components include symptoms associated with the potential side effect of high calcium levels. These can include feelings of lethargy, sluggishness, and sometimes headache, which may be interpreted as fatigue or affect alertness.


Q: Is it normal to feel a change in symptoms within the first week of using Osteoplus?

Since the time to reach the full therapeutic effect on mineral balance is documented as being longer (approximately one month), a significant change in overall symptoms may not be observed within the first seven days of use.


Q: Is Osteoplus an opioid or habit-forming drug?

Osteoplus is classified by regulatory agencies as a Mineral Supplement and Vitamin D Analog. It is not classified as an opioid or as a controlled substance, and the official labeling does not contain warnings about the potential for habit formation or drug dependency.


Q: Has Osteoplus been reviewed or approved by the FDA (or similar agencies)?

The components of the drug are published in official drug information sources, such as the FDA’s DailyMed and the NIH. This confirms that the medicine is subject to the required regulatory oversight and review processes for its use and distribution.


Q: Do older adults use Osteoplus differently than younger adults?

Official guidance often notes that dose selection for older adults should be cautious, typically starting at the lower end of the dosing range. This cautious approach reflects general safety practices for older adults.


Q: What is the typical timeframe for Osteoplus to stay in the body?

Official pharmacokinetics data indicate that the Dihydrotachysterol component has a relatively short half-life compared to other Vitamin D forms. This characteristic helps in the management of calcium levels, as high calcium levels can potentially reverse more quickly compared to other Vitamin D forms should treatment need to be suspended.


Q: What should be done before stopping treatment with Osteoplus?

Official guidelines indicate that the individualized treatment can be suspended by a professional if the patient develops hypercalcemia. Regulatory documents indicate that discontinuation of the medicine should be managed in consultation with a healthcare professional.


Q: Can Osteoplus impact coordination or the ability to drive?

The adverse reactions listed in official documents include symptoms like headache, lethargy, and sluggishness, particularly if calcium levels become too high. Because symptoms like lethargy or sluggishness are noted, individuals should consider how they react to the medication before engaging in activities that require full alertness or coordination.


Q: Is a follow-up appointment needed after starting Osteoplus?

Official prescribing information requires frequent, mandatory professional monitoring of serum calcium levels throughout the course of treatment. This essential monitoring necessitates regular interaction, such as follow-up appointments, with a healthcare professional to safely manage the highly individualized dose.


Q: Are there known interactions between Osteoplus and psychiatric medicines?

While the regulatory documents list specific contraindicated and clinically significant interactions, psychiatric medicines are not listed as a class with known major conflicts. However, the potential for interactions exists with any medicine that affects the liver or electrolyte balance. Review of all concomitant medications by a healthcare professional is always recommended.


Q: Is Osteoplus available without a prescription anywhere?

The Dihydrotachysterol component of Osteoplus is officially classified as a prescription-only (Rx) medicine. This classification is primarily due to the requirement for highly individualized dosing and mandatory, frequent professional laboratory monitoring to prevent the serious side effect of hypercalcemia.


Q: Is it necessary to take Osteoplus at the exact same time every day?

Official administration guidelines state the medication is taken as a once-daily dose, and the Calcium Carbonate component should generally be taken with meals for best absorption. Consistent daily timing may contribute to maintaining steady levels, but the regulatory text specifies a once-daily dose.

How should Osteoplus be stored and disposed of?

Storage and Handling Requirements

Osteoplus must be stored under specific conditions to maintain the stability of its active ingredients. The product should be kept at Controlled Room Temperature, typically ranging from 15 C to 30 C. It is mandatory to protect the medicine from light and excessive moisture due to the sensitivity of the Dihydrotachysterol component. Therefore, the product must be preserved in its tight, light-resistant container until use.

All medicines must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

To dispose of unused or expired Osteoplus, the preferred method is utilizing a community drug take-back program. If this option is unavailable, the medicine should not be thrown directly into the trash or poured into the wastewater system. Instead, mix the product with an undesirable substance, such as coffee grounds or cat litter, and seal the mixture in a container before discarding it with household waste, following the standard regulatory procedure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Osteoplus found in:

A-Z Index: